I2Pure Hires Healthcare Industry Leader as Chief Executive Officer
Jeffrey Jochims Assumes Role of I2Pure CEO

Ashburn, Virginia – November 7, 2023 – Today, I2Pure announced the hiring of its new Chief Executive Officer, Jeffrey Jochims, effective November 1, 2023. Jeff succeeds I2Pure Founder Douglas Spitz, who is transitioning to the role of Executive Chair. Jochims also joins the I2Pure Board of Directors.

Jochims assumes this role following more than 25 years of leadership in the life sciences and healthcare industries, including long executive tenures at industry leaders Thermo Fisher Scientific and Owens & Minor. In addition, Jochims has deep experience in entrepreneurial start-ups as well as global life sciences and healthcare companies of all sizes. Businesses under Jochims’ influence have consistently delivered customer-centric operational excellence and market share gains.

“I2Pure has made tremendous progress since our formation only a few years ago. We’re elated to have someone of Jeff’s experience and capabilities join our company as Chief Executive Officer,” said Doug Spitz, I2Pure Founder. “Based on the incredible reception to our innovative iodine applications and the momentum that we’re building, the time arrived for I2Pure to bring on a seasoned executive that can lead us into the future. We’re humbled and proud that I2Pure has been able to attract and retain an executive leader of Jeff’s caliber. For more than two decades, Jeff has been highly successful in leading global businesses across the life sciences and healthcare industries,” continued Spitz.

“Rarely does a business present the kind of revolutionary and disruptive capabilities that I2Pure offers to healthcare and biosafety,” said Jochims. “This is truly a once-in-a-career opportunity to be part of something that can change healthcare and the world for decades into the future. Think of anesthesia, think of the polio vaccine. That is the kind of potential that I2Pure represents. It is exhilarating to take the helm of this incredible company and to work alongside its visionary founders to realize the potential of I2Pure,” he concluded.

With Jochims’ hiring, Doug Spitz transitions to the role of Executive Chair, succeeding Joseph Steinberg, who will remain on the I2Pure Board of Directors.

---

For more information about I2Pure contact Abigail Moses at abigail@i2pure.com.

Download

         

Recent Publications

---

I2Pure awarded 2nd place in the International Competition Genius Challenge

In order to promote the technological development of solutions around the use and applications of iodine and its derivatives, and in line with its commitment to enabling a more sustainable industry and making the world a better place to live, SQM, the leader and main producer of iodine globally with support of Expande, launched “Genius”; an open innovation call that seeks identifying the best solutions that encourage the use of this element and its derivatives in Chile and at an international level.

About the Genius Challenge

For those researching PVP-I

---

In consideration of your research using PVP-I, we would like to introduce you to an iodine formulation that has stabilized molecular iodine (I₂) without the presence of complexing agents or other iodine species.

I2PURE is a biotechnology company on a mission to provide a means of combating effects of pathogens on global societies. The I2PURE platform is being developed for OTC, therapeutic, medical device and agricultural usage. I2PURE’s molecular iodine chemistry creates a non-staining, non-irritating, efficacious ingredient with 1,500 ppm of active I₂. It is third party certified nontoxic in a 24-hour in vitro cytotoxicity study.

---

Molecular iodine is not responsible for cytotoxicity in iodophors

Journal of Hospital Infection - February 4, 2022

---

For the last 67 years, there has been a lack of accurate information presented to global healthcare providers regarding molecular iodine. This foundational manuscript in The Journal of Hospital Infections will begin to contextualize molecular iodine for the first time.

The conclusion of the manuscript: "The maximum concentration of I₂ found in diluted PVP, about 25 ppm, is not cytotoxic or irritating. The potential clinical utility of I₂ has been limited by incorporating this broad-spectrum biocide in acidic aqueous formulations that contain numerous chemical species that contribute toxicity but not biocidal activity. I₂ can be delivered topically into hypodermis tissue without irritation."

Read the manuscript

---

I2PURE recognized as the Runner Up winner in the Tech Venture category.

Loudoun Economic Development - July 28, 2021

---

We are a winner in the second annual Loudoun Innovation Challenge and have taken the Tech Venture category top spot. This year had an enormous amount of competition with a total of 156 applicants. We are thrilled to have stood out among so many inventive and forward-thinking businesses.

This competition is designed to recognize Loudoun County Virginia local companies that are rethinking the status quo in their industries.

“This is a tremendous honor for I2PURE, and the recognition of I2PURE’s innovation, mission and work during the startup phase is gratifying,” CEO Douglas Spitz said. “From its inception, I2PURE has been privileged to call Loudoun County home. We have been welcomed here since day one and cannot imagine growing our global biotechnology company anywhere else”.

Thank you so much Loudoun County Economic Development Authority, in partnership with Loudoun Economic Development. We are honored!